Abel, S

Allavena, C

Cuzin, L

Duvivier, C

Finkielsztejn, L

Levy-Bachelot, L

Mellliez, H

Poizot-Martin, I

Pugliese, P

Valantin, MA

English

PubMed

L Cuzin

C Allavena

L Levy-Bachelot

MA Valantin

H Mellliez

P Pugliese

I Poizot-Martin

C Duvivier

L Finkielsztejn

S Abel

Springer - Publisher Connector

Tolerance and durability of abacavir/lamivudine (ABC/3TC)-containing regimens: results from a large prospective French cohort

POSTER PRESENTATION Open Access
Tolerance and durability of abacavir/lamivudine
(ABC/3TC)-containing regimens: results from a
large prospective French cohort
L Cuzin1, C Allavena2*, L Levy-Bachelot3, MA Valantin4, H Mellliez5, P Pugliese6, I Poizot-Martin7, C Duvivier8,
L Finkielsztejn9, S Abel10
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
Methods
Patients (pts) were selected from the Dat’AIDS French
prospective cohort if they were prescribed an ABC/3TC
containing regimen for the first time between 01/01/
2004 and 31/12/2007 and were still actively followed on
31/05/2008 as to ensure sufficient follow-up. All causes
of treatment discontinuation were recorded, as well as
immuno-virological data and cardiovascular events (CE)
during follow-up.
Results
Among the 1704 pts included in the study (male 70%,
mean age 43 years, HBV or HCV co-infection 24.1%)
407 (24%) were antiretroviral (ARV) naïve, 696 (41%)
were virologically controlled on ARV treatment (switch),
and 601 (35%) were on treatment with detectable VL
(failure) at time of ABC/3TC initiation. Previous treat-
ment with 3TC was noted in 92% of the pretreated pts.
With a median duration of follow-up of 496 days, the
population represents 2636 pts-year.
Overall 565pts (33%) discontinued ABC/3TC combi-
nation during follow-up (36%, 24%, and 42% of the
naive, switch and failure groups, respectively). Reasons
for discontinuation were poor tolerance in 41% of the
cases, including suspected hypersensitivity (HSR) in 4%
of the overall population, treatment failure in 20%, and
other causes in 39%. This distribution was not different
if pts received either a NNRTI (20% of the pts) or a
boosted protease inhibitor (46%) in their regimen.
Median time to discontinuation was 4.3 years overall
and less than one month in case of suspected HSR.
Discontinuation for bad tolerance was observed in
38%, 54%, and 35% of the naïve, switch and failure
populations respectively, whereas treatment failure was
responsible for discontinuation in 15%, 10%, and 29%
of the same populations. Major CE were reported in
21 cases (0.08% py). Death was recorded in 27 cases, 9
deaths being AIDS related, 6 related to liver diseases, 6
to cancer, 2 to vascular accidents (1 cardiac, 1 neuro-
logical), 1 accidental, and 3 unknown. At M24, prob-
ability of still receiving ABC/3TC was 62%, 77%, and
60% respectively for the defined groups, and VL on
treatment was below detection for 86%, 90%, and 71%
of them, respectively.
Conclusion
In this population of pts who received ABC/3TC con-
taining regimens before HLA screening was routinely
available, treatment was maintained with virological suc-
cess for more than 2 years. Poor tolerance was the main
reason for early discontinuation, and was not different if
the pts received either NNRTI or boosted PI in their
regimen. CE were rare.
Author details
1CHU Toulouse, COREVIH Midi Pyrénées Limousin, Toulouse, France.
2University Hospital Nantes, Infectious Diseases Department, Nantes, France.
3Laboratoire GlaxoSmithKline, Marly-le-Roi, France. 4AP-HP Pitié-Salpêtrière
Hospital, Paris, France. 5Centre hospitalier de Tourcoing, Service Universitaire
des Maladies infectieuses, Tourcoing, France. 6Nice University Hospital,
Infectious Disease Dpt, Nice, France. 7Hôpital Sainte-Marguerite, Service
2University Hospital Nantes, Infectious Diseases Department, Nantes, France
Full list of author information is available at the end of the article
Cuzin et al. Journal of the International AIDS Society 2010, 13(Suppl 4):P44
http://www.jiasociety.org/content/13/S4/P44
© 2010 Allavena et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
d’Immuno-Hématologie Clinique, C.I.C., Marseille, France. 8Institut pasteur,
Centre Médical de l’Institut Pasteur, Paris, France. 9ViiV Healthcare France,
Département Médical, Marly le Roi, France. 10CHU de Fort-de-France,
Infectious Disease Dpt, CIC-EC 802 Antilles Guyane, Fort-de-France,
Martinique (French).
Published: 8 November 2010
doi:10.1186/1758-2652-13-S4-P44
Cite this article as: Cuzin et al.: Tolerance and durability of abacavir/
lamivudine (ABC/3TC)-containing regimens: results from a large
prospective French cohort. Journal of the International AIDS Society 2010
13(Suppl 4):P44.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cuzin et al. Journal of the International AIDS Society 2010, 13(Suppl 4):P44
http://www.jiasociety.org/content/13/S4/P44
Page 2 of 2


Crossref

Journal of the International AIDS Society

http://doaj.org/search?source=%7B%22query%22%3A%7B%22bool%22%3A%7B%22must%22%3A%5B%7B%22term%22%3A%7B%22id%22%3A%22fe7a772e261443ada7a1534c2bab59c0%22%7D%7D%5D%7D%7D%7D

Tolerance and durability of abacavir/lamivudine (ABC/3TC)-containing regimens: results from a large prospective French cohort

Abstract

Similar works

Full text

Available Versions

Springer - Publisher Connector

Springer - Publisher Connector

Crossref